Year archive

Swedish Orphan Biovitrum — 2012 filings

All 65 regulatory filings released by Swedish Orphan Biovitrum (SOBI) in 2012, sourced directly from the official regulator.

65 Filings

2012 Period

2012 filings (65)

Filing	Released	Lang
Sobi files to expand Kineret® label to include CAPS Regulatory Filings	2012-11-19	English
Sobi ansöker om utvidgning av indikationen för Kineret® att även omfatta CAPS Investor Presentation	2012-11-19	Swedish
Sobi to list bond loan on NASDAQ OMX Stockholm and publishes prospectus Capital/Financing Update	2012-11-12	English
Sobi noterar obligationslån på NASDAQ OMX Stockholm och offentliggör prospekt Capital/Financing Update	2012-11-12	Swedish
BIOGEN IDEC AND SOBI ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING LONG-LASTING RECOMBINANT FACTOR VIII FC FUSION PROTEIN IN HEMOPHILIA A Earnings Release FY 2012	2012-10-31	English
BIOGEN IDEC OCH SOBI MEDDELAR POSITIVA RESULTAT FRÅN FAS III STUDIEN AVSEENDE LÅNGVERKANDE REKOMBINANT FAKTOR VIII FC FUSIONSPROTEIN FÖR BEHANDLING AV HEMOFILI A Regulatory Filings	2012-10-31	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report 9M 2012	2012-10-30	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report 9M 2012	2012-10-30	English
Delårsrapport januari - september 2012 Interim / Quarterly Report 9M 2012	2012-10-30	Swedish
Interim Report, January -September 2012 Interim / Quarterly Report 9M 2012	2012-10-30	English
Jörgen Winroth ansvarig för Investor Relations på Sobi Board/Management Information	2012-10-10	Swedish
Jorgen Winroth joins Sobi to lead Investor Relations Board/Management Information	2012-10-10	English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB (publ) Declaration of Voting Results & Voting Rights Announcements	2012-09-28	Swedish
New number of shares and votes in Swedish Orphan Biovitrum AB (publ) Declaration of Voting Results & Voting Rights Announcements	2012-09-28	English
BIOGEN IDEC AND SOBI MEDDELAR POSITIVA RESULTAT FRÅN FAS III STUDIEN AVSEENDE LÅNGVERKANDE REKOMBINANT FAKTOR IX FC FUSIONSPROTEIN FÖR BEHANDLING AV HEMOFILI B. Regulatory Filings	2012-09-26	Swedish
BIOGEN IDEC AND SOBI ANNOUNCE POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY INVESTIGATING LONG-LASTING RECOMBINANT FACTOR IX FC FUSION PROTEIN IN HEMOPHILIA B Earnings Release FY 2012	2012-09-26	English
Styrelsen utnyttjar återköpsbemyndigande för säkerställande av bolagets åtaganden enligt incitamentsprogram Share Issue/Capital Change	2012-09-14	Swedish
The board of directors exercises authorization for repurchase of shares for the purpose of securing the company's commitments under the incentive program Transaction in Own Shares	2012-09-14	English
Interim / Quarterly Report 2012 Interim / Quarterly Report Q2 2012	2012-07-19	English
Interim / Quarterly Report 2012 Interim / Quarterly Report Q2 2012	2012-07-19	Swedish
Sobi ingår forskningssamarbete med Affibody inom IL-1 området Regulatory Filings	2012-07-10	Swedish
Sobi enters Research Collaboration with Affibody within the IL-1 field Regulatory Filings	2012-07-10	English
Sobi ansöker om godkännande av Kineret för NOMID i USA Regulatory Filings	2012-07-06	Swedish
Sobi files for NOMID indication for Kineret in US Regulatory Filings	2012-07-06	English
Biogen Idec och Sobi initierar globala kliniska barnstudier med långverkande produktkandidater inom hemofili A och B Regulatory Filings	2012-07-05	Swedish
Biogen Idec and Sobi Initiate Global Clinical Trials of Long-Lasting Hemophilia A and B Product Candidates in Children Investor Presentation	2012-07-05	English
Ändring av antalet aktier och röster i Swedish Orphan Biovitrum AB Declaration of Voting Results & Voting Rights Announcements	2012-06-29	Swedish
Change in number of shares and votes in Swedish Orphan Biovitrum AB Declaration of Voting Results & Voting Rights Announcements	2012-06-29	English
Sobi emitterar 5-årigt obligationslån på 600 Mkr Capital/Financing Update	2012-06-18	Swedish
Sobi issues 5-year SEK 600m bond Capital/Financing Update	2012-06-18	English
Sobi omfinansierar befintlig kreditfacilitet Capital/Financing Update	2012-06-05	Swedish
Sobi to refinance existing credit facility Capital/Financing Update	2012-06-05	English
Sobi har utnämnt Birgitte Volck till Chief Medical Officer Board/Management Information	2012-05-31	Swedish
Sobi appoints Birgitte Volck as Chief Medical Officer Board/Management Information	2012-05-31	English
Major Shareholding Notification 2012 Major Shareholding Notification	2012-05-28	English
Major Shareholding Notification 2012 Major Shareholding Notification	2012-05-25	English
Sobi : Kommuniké från Swedish Orphan Biovitrums ("Sobi") årsstämma AGM Information	2012-04-26	Swedish
Sobi:Resolutions from Swedish Orphan Biovitrum's ("Sobi") Annual General Meeting (AGM) AGM Information	2012-04-26	English
Interim / Quarterly Report 2012 Interim / Quarterly Report Q1 2012	2012-04-26	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report Q1 2012	2012-04-26	English
Sobi :Styrelsen utnyttjar emissions- och återköpsbemyndigande för säkerställande av bolagets åtaganden enligt långsiktiga prestationsbaserade aktieprogram Transaction in Own Shares	2012-04-24	Swedish
Sobi: The board of directors exercises authorization for share issuance and repurchase of shares Transaction in Own Shares	2012-04-24	English
Annual Report 2011 Annual Report FY 2011	2012-04-05	English
Sobis årsredovisning publicerad på webben Report Publication Announcement	2012-04-05	Swedish
Sobi's Annual Report published on the web Report Publication Announcement	2012-04-05	English
Annual Report 2011 Annual Report FY 2011	2012-04-05	Swedish
Sobi ingår tilläggsavtal med säljarna av Arexis AB M&A Activity	2012-03-30	Swedish
Sobi amends its agreement with sellers of Arexis AB Legal Proceedings Report	2012-03-30	English
Kallelse till årsstämma i Swedish Orphan Biovitrum AB (publ) AGM Information	2012-03-26	Swedish
Notice of annual general meeting in Swedish Orphan Biovitrum AB (publ) AGM Information	2012-03-26	English
Ekonomi- och finansdirektör Lars Sandström lämnar Sobi Board/Management Information	2012-03-20	Swedish
CFO Lars Sandström to leave Sobi Board/Management Information	2012-03-20	English
Interim / Quarterly Report 2011 Interim / Quarterly Report Q4 2011	2012-02-23	Swedish
Earnings Release 2011 Earnings Release Q4 2011	2012-02-23	English
Major Shareholding Notification 2012 Major Shareholding Notification	2012-02-17	English
Tillverkningsavtalet med Pfizer för ReFacto AF®/XYNTHA förlängt t o m 2020 Regulatory Filings	2012-02-16	Swedish
ReFacto AF®/XYNTHA® Supply Agreement Extended until 2020 Regulatory Filings	2012-02-16	English
Sobis avtal med Biogen Idec avseende hemofiliprogrammen rFVIIIFc och rFIXFc M&A Activity	2012-02-06	Swedish
Sobi's agreement with Biogen Idec regarding long-lasting rFVIIIFc and rFIXFc hemophilia programs Regulatory Filings	2012-02-06	English
Sobi: Wills Hughes-Wilson utsedd till Vice President, Government Affairs & Policy Board/Management Information	2012-01-31	Swedish
Sobi: Wills Hughes-Wilson appointed Vice President Government Affairs & Policy Board/Management Information	2012-01-31	English
Alan Raffensperger utsedd till Chief Operating Officer Board/Management Information	2012-01-17	Swedish
Alan Raffensperger appointed Chief Operating Officer Board/Management Information	2012-01-17	English
Sobi tecknar licensavtal för ny behandling inom neonatalområdet med Only For Children Pharmaceuticals Capital/Financing Update	2012-01-13	Swedish
Sobi signs global licensing agreement for novel neonatology treatment from Only for Children Pharmaceuticals Regulatory Filings	2012-01-13	English

Filings by year

2026 16 filings
2025 35 filings
2024 29 filings
2023 48 filings
2022 23 filings
2021 31 filings
2020 44 filings
2019 38 filings
2018 31 filings
2017 34 filings
2016 47 filings
2015 52 filings
2014 58 filings
2013 79 filings
2012 65 filings
2011 51 filings
2010 78 filings
2009 69 filings
2008 51 filings
2007 10 filings